Bacteroides fragilis group organisms are not only the most frequently isolated anaerobes in human infections, but also the most common cause of anaerobic bacteremia with a relatively high rate of mortality [1] [2] [3] [4] Results : Eight isolates were resistant to imipenem. Additionally, the resistance rates to cefotetan were decreased in B. thetaiotaomicron, while those for clindamycin were significantly increased compared to the rates found in previous studies. Depending on species, resistance rates were 1-4% for imipenem, 1-6% for piperacillin-tazobactam, 4-11% for cefoxitin, 33-49% for piperacillin, 14-60% for cefotetan, and 51-76% for clindamycin. No isolates were resistant to chloramphenicol or metronidazole.
eggerthii, B. merdae, and B. stercori. Increasing resistance to antimicrobial agents is a significant problem among anaerobic bacteria [5, 6] . Clinical outcome of B. fragilis group infection is also affected by appropriate antimicrobial agent treatment [7] . In our previous studies, B. fragilis group organisms in Korea were shown to be more frequently resistant to various antimicrobial agents than in other countries [8, 9] . The CLSI does not recommend routine susceptibility testing for anaerobic microbes [10] . Instead, periodic monitoring of the regional resistance trends of clinically important anaerobes, including B. fragilis group isolates, need to be performed to assist in the selection of empirical antimicrobial agents to treat these anaerobic infections [11] . However, there have been no recent studies on susceptibility testing against B. fragilis group isolates from Korea. Therefore, providing current susceptibility patterns of these isolates is very important for appropriate empirical antimicrobial therapy.
In this study, we attempted to determine the current susceptibilities of B. fragilis group organisms isolated from patients in Korea during a 8-yr peoriod (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) ).
MATERIALS AND METHODS

Isolates
All B. fragilis group organisms were isolated between 1997 and 2004 from various clinical specimens (blood, body fluid, and pus) in a university hospital in Korea. The specimens were inoculated on phenyl ethyl alcohol blood agar plates and in thioglycolate broth, which were then incubated at 37℃ for 48 hr in an anaerobic chamber (Forma, Marietta, OH, USA) with an atmosphere of 10% H2, 10% CO2, and 80% N2. Gram stain was performed as preliminary examination. The isolates were identified by conventional methods, ANI card (bioMerieux, Marcy l' Etoile, France, and/or the ATB 32A system (bioMerieux, Marcy l' Etoile, France) [12, 13] . The isolates were stored at -70℃ in 20% skim milk (BBL Microbiology Systems, Cockeysville, MD, USA) until used for the study. anaerobic bacteria were applied to interpret the MICs [10] .
Antimicrobial susceptibility
RESULTS
A total of 466 nonduplicate clinical isolates of B. fragilis groups organisms, which were isolated during an 8-yr period, were tested for their susceptibility to antibiotics ( thetaiotaomicron, and other Bacteroides spp, respectively.
Piperacillin and cefotetan were less active and most strains tested (90%) were inhibited by these drugs at >256 and ≥128 μ g/mL, respectively. The resistance rates to clindamycin were 51% in B. fragilis, 76% in B. thetaiotaomicron, and 74% in other Bacteroides spp. All the strains were inhibited by ≤8 μ g/mL of chloramphenicol or metronidazole, to which no isolates were resistant. The resistance rates to various antimicrobial agents of the non-fragilis species were higher than those of B. fragilis ( Table 2 ). 
DISCUSSION
In this study, the susceptibilities of 466 isolates of B.
fragilis group organisms to various antimicrobial agents were determined. Among β -lactam agents, imipenem was the most active, but three B. fragilis, two B. thetaiotaomicron and three B. distasonis isolates were inhibited by of the strongest β -lactamase inducers, it is recommended for the treatment of anaerobic infections, especially intra-abdominal infections, because carbapenems are highly active against polymicrobial infection including B. fragilis group organisms and other Enterobacteriacea [14] . The imipenem resistance rate of B. fragilis group isolates in this study (1.9%) was similar to rates of 0.6-1.3% seen in Europe, 0.4% in Spain, and 0.5% in the USA [15] [16] [17] . A well-known mechanism of carbapenem resistance in B. fragilis group is cfiA and insertion sequence (IS) elements [18] . Presenting cfiA and IS elements simultaneously, can reduce susceptibility to carbapenems [19, 20] .
Most B. fragilis group organisms are naturally resistant to many penicillins and cephalosporins because of their production of chromosomal class A β -lactamases with predominantly cephalosporinase activity [21] . However, the combination of these drugs with β -lactamase inhibitors restores the antimicrobial activity of β -lactams. In this study, the resistance rates for piperacillin were 33-49% (Table 2) , an increase of approximately 10% in comparison with previous Korean studies [9] . However, the resistance rates to piperacillin-tazobactam were ≤1% for B. fragilis and 4-6% for non-fragilis species. Piperacillintazobactam was more active than piperacillin alone against B. fragilis groups in vitro and other in vivo study [22] .
Cefoxitin and cefotetan are cephamycin group antimicrobial agents that are commonly used for aerobic and anaerobic infections. However, the resistance rates to both of the cephamycins were significantly different depending on the species of bacteria tested. The resistance rates to cefoxitin, the third most active β -lactam in this study, were 4-11% overall for B. fragilis group isolates, and these rates were not significantly higher as compared with previous studies, especially the rates for B. fragilis [9, 23] .
However, the resistance rates to cefotetan (14-60%) were significantly higher than those to cefoxitin. It is interest- [24] . Clindamycin resistance of anaerobes is due to an alteration in ribosome as the target site, which is similar to the cause of macrolidelincosamide-streptogramin resistance in staphylococci [25] .
Chloramphenicol and metronidazole are still the most active non-β -lactam agents against anaerobic bacteria.
None of the isolates were found to be resistant to these drugs (≤8 μ g/mL) in this study, although one strain resistant to metronidazole has been reported in the U.S. [6, [26] [27] [28] .
In conclusion, this study provides insights into the current resistance trends of various species of the B. fragilis group. Among β -lactam agents, imipenem, piperacillin-tazobactam, and cefoxitin are still active against B. fragilis group organisms and they can be used for empirical therapy. Metronidazole and chloramphenicol retain excellent in vitro antimicrobial activities against this group of bacteria and they are still useful for clinical cases. Continuous investigation will be required to demonstrate continuing changes in susceptibility patterns of B. fragilis group isolates.
